PD Dr. med. Arnoud Templeton

  • Ribnikar D, Goldvaser H Veitch ZW, Ocana A, Templeton AJ, Seruga B, Amir E. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. 2020 Cancer Medicine. [in press]
  • Wallrabenstein T, del Rio J, Templeton AJ, Buess MA. Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer.  PLOS One 2020; [in press]
  • Templeton AJ, Amir E, Tannock IF. Informative censoring – a neglected cause of bias in oncology trial. Nature Reviews Clinical Oncology; 2020 [in press].
  • Templeton AJ, Booth CM, Tannock IF.  Informing Patients about Expected Outcomes: The Efficacy-Effectiveness Gap. J Clin Oncol. 2020 Mar 11:JCO1902035. doi: 10.1200/JCO.19.02035.
  • Tannock IF, Templeton AJ; Flawed Trials for Cancer. Annals of Oncology; 2019.
  • Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, VerdinesPerez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE; Adjuvant Radiation Therapy after Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Oncol. 2019 Jul; 2(4): 448–455.
  • Hansen AR, Tannock IF, Templeton AJ, Chen X, Evans A, Knox J, Prawira A, Sridhar S, Tan Q, Vera-Badillo F, Wang L, Wouters B, Joshua AM; Phase II trial of high dose pantoprazole (autophagy inhibitor) with docetaxel in metastatic Castration-Resistant Prostate Cancer (mCRPC). Oncologist. 2019 Apr 5.
  • Rodríguez-Fernández IA, Rodríguez-Romo L, Hernandez-Barajas D, Gonzalez-Conchas GA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, Amir E, Vera-Badillo FE. Adjuvant Radiation Therapy after Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Oncology. 2018 [in press].
  • Templeton AJ, Ocana A, Tannock IF. How to Become a Researcher. ESMO Handbook Oncological Study Publications 2018; 11: 146–154.
  • Schmid T, Templeton AJ. Highlights vom ASCO zum metastasierten Prostatakarzinom. Leading Opinions Hämatologie & Onkologie 2018; 5: 20–23.
  • Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E. Reporting of randomized trials in common cancers in the lay media. Oncology; 2018; 94: 65–71.
  • Bojaxhiu B, Templeton AJ, Elicin O, Shelan M, Zaugg K, Walser M, Giger R, Aebersold D, Dal Pra A. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-)radiation. Radiation Oncology. 2018 Nov 6; 13(1): 216.
  • Omlin A, Spahn M, Beyer J, Eberli D, Gillessen S, Jochum W, Kueng M, Nitzsche E, Rentsch CA, Roggero E, Schmid H-P, Stenner F, Templeton AJ, Wild D, Wyler S, Zwahlen D, Cathomas R. Medikamentöse Behandlung des metastasierten Prostatakarzinoms – eine interdisziplinäre Empfehlung. Swiss Med Weekly 2018 Sep; 107(19): 1043–1051.
  • Armstrong AJ., Lin P., Higano CS., Sternberg CN., Sonpavde G., Tombal B., Templeton AJ., Fizazi K., Phung D., Wong EK., Krivoshik A., Beer TM.Development and validation of aprognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Annals of Oncology. 2018 Sep 10.

  • Templeton AJ., Rodríguez Lescure A., Ruíz A., Alba E., Calvo L., Ruíz Borrego M., Santaballa A., Rodríguez CA., Crespo C., Ramos M., Gracia Marco J., Lluch A., Álvarez I., Casas M., Sánchez-Aragó M., Caballero R., Carrasco E., Amir E., Martin M., Ocaña A. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/ 9906 substudy. Clin Transl Oncol.2018 May 15.
  • Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, Barnadas A, Booth CM, Amir E.Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. J Natl Cancer Inst. 2018 May 1; 110(5): 486–492.
  • Tibau A., Anguera G., Andrés-Pretel F., Templeton AJ., Seruga B., Barnadas A., Amir E., Ocana A. Oncotarget. Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. 2018 Feb 28; 9(19): 15061–15067.
  • Baumann M, Dani SU, Dietrich D, Hochstrasser A, Klingbiel D, Mark MT, Riesen WF, Ruhstaller T, Templeton AJ, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. Swiss Med Wkly. 2018 Jan 16; 148: w14576
  • Templeton A.: Level-1- Evidenz für den frühen Einsatz von Abirateron beim metastasierten kastrationsnaiven Prostatakarzinom. Leading Opinions Urologie (2017); 2: 9-12
  • Schmid T., Templeton A.: Nierenzellkarzinom - aktuelle Therapieoptionen. Onco Mag - Das Schweizer Onkologie- Magazin (2017); 3: 20-3
  • Baumann M., Dani S., Dietrich D., Hochstrasser A., Klingbiel D., Mark M., Riesen W., Ruhstaller T., Templeton A., Thürlimann B.: Vitamin D Levels in Swiss Breast Cancer Survivors. Swiss Med Wkly 2017
  • Tibau A., Molto C., Ocana A., Templeton A., Del Carpio L., Del Paggio J., Barnadas A., Booth C., Amir E.: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. J Natl Cancer Inst (2017)
  • Ribnikar D., Goldvaser H., Ocana A., Templeton A., Seruga B., Amir E.: Reporting of Randomized Trials in Common Cancers in the Lay Media. Oncology. 2017 Nov 18
  • Gonzalez-Conchas G., Rodriguez- Romo L., Hernandez Barajas D., Gonzalez-Guerrero J., Rodriguez- Fernandez I., Verdines-Perez A., Templeton A., Ocana A., Seruga B., Tannock I., Amir E., Vera-Badillo F.: Epidermal Growth Factor Receptor Overexpression and Outcomes in Early Breast Cancer: A Systematic Review and a Meta-Analysis. Cancer Treat Rev. 2017 Oct 31; 62: 1-8
  • Klein S., Kohler S., Krüerke D., Templeton A., Weibel A., Haraldsson E., Nahm M., Wolf U.: End-of-Life Experiences: A Survey Amongst Physicians and Nurses in a Hospital for Anthroposophically Extended Medicine. Complement Med Res. 2017 Oct 26
  • Niraula S., Templeton A., Vera-Badillo F., Dodd A., Nugent Z., Joshua A., Tannock I.: Suppression of Bone Turnover Following Zoledronic Acid in Men with Metastatic Castration- Resistant Prostate Cancer. Future Science OA. 2017 Oct 20
  • Goldvaser H., AlGorashi I., Ribnikar D., Seruga B., Templeton A., Ocana A., Amir E.: Efficacy of Extended Adjuvant Therapy with Aromatase Inhibitors in Early Breast Cancer among Common Clinicopathologically-Defined Subgroups: A Systematic Review and Meta-Analysis. Cancer Treat Rev. 2017 Sep; 59: 46-53
  • Diem S., Schmid S., Krapf M., Flatz L., Born D., Jochum W., Templeton A., Früh M.: Neutrophilto- Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients with Non-Small Cell Lung Cancer (NSCLC) treated with Nivolumab. Lung Cancer. 2017 Sep; 111: 176-81
  • Goldvaser H., Ribnikar D., Fazelzad R., Seruga B., Templeton A., Ocana A., Amir E.: Influence of Non-Measurable Disease on Progression-Free Survival in Patients with Metastatic Breast Cancer. Cancer Treat Rev. 2017 Sep; 59: 46-53
  • Ocana A., Nieto-Jiménez C., Pandiella A., Templeton A.: Neutrophils in Cancer: Prognostic Role and Therapeutic Strategies. Mol Cancer. 2017 Aug 15; 16(1): 137
  • Kulkarni G., Hermanns T., Wie Y., Bhindi B., Satkunasivam R., Athanasopoulos P., Bostrom P., Kuk C., Li K., Templeton A., Sridhar S., van der Kwast T., Chung P., Bristow R., Milosevic M., Warde P., Fleshner N., Jewett M., Bashir S., Zlotta A.: A Propensity Score Analysis of Radical Cystectomy versus Bladder- Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017 Jul 10; 35(20): 2299-305
  • Adam R., Diez-Gonzalez L., Ocana A., Seruga A., Amir E., Templeton A.: Prognostic Role of Telomere Length in Malignancies: A Meta- Analysis and Meta-Regression. Exp Mol Pathol. 2017 May 12
  • Barnes T., Amir E., Templeton A., Gomez Garcia S., Navarro B., Seruga B., Ocana A.: Efficacy, Safety, Tolerability and Price of Newly Approved Drugs in Solid Tumors. Cancer Treat Rev. 2017 May; 56: 1-7
  • Tibau A., Diez-Gonzalez L., Navarro B., Templeton A., Seruga B., Pandiella A., Amir E., Ocana A.: Impact of Availability of Companion Diagnostics on Clinical Development of Anti-Cancer Drugs. Mol Diagn Ther. 2017 Feb 28
  • Ethier J., Desautels D., Templeton A., Oza A., Amir E., Lheureux S.: Is the Neutrophil-to-Lymphocyte Ratio Prognostic of Survival Outcomes in Gynecologic Cancers? A Systematic Review and Meta-Analysis. Gynecol Oncol. 2017 Feb 17
  • Ethier J., Desautels D., Templeton A., Shah P., Amir E.: Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Res. 2017 Jan 5; 19(1): 2.
  • Tannock I., Amir E., Booth C. M., Niraula S., Ocana A., Seruga B., Templeton A., Vera-Badillo F.: The relevance of randomized controlled trials to clinical practice. Lancet Oncol. Dec 2016: 17(12): e560–e567
  • Ethier J-L, Desautels D, Templeton AJ, Shah P, Amir E. Prognostic Role of
    Neutrophil-to-Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Research 2016[accepted for publication 05-Dec-2016] IF 5.211 (JCI 2015, rank 32/213 oncology)
  • Dearnaley D., Inge van Oort I., Templeton A.: Metastatic Prostate Cancer. In: Summary of Science of Practice – Metastatic Prostate Cancer. Published by Mirrors of Medicine eHIMS bvba, Lier, Belgium 2016: 7–34
  • Srikanthan A., Vera-Badillo F., Ethier J. L., Goldstein R., Templeton A. J., Ocana A., Seruga B., Amir E.: Evolution in the Eligibility Criteria of Randomized Controlled Trials for Systemic Cancer Therapies. Cancer Treatment Reviews 2016: 43: 67–73
  • Ethier J. L., Desautels D., Templeton A. J., Shah P., Amir E.: Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Research 2016
  • Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SMH, Chan A-W, Ocana A, Templeton AJ, Seruga B, Amir E, Tannock IF. Honorary and Ghost-Authorship in Reports of Randomized Clinical Trials in Oncology. Eur J Cancer. 2016 Oct;66:1-8. Aug 6. IF 6.163 (JCI 2015, rank 22/213oncology)
  • Vera-Badillo F., Napoleone M., Krzyzanowska M., Alibhai S., Chan A., Ocana A., Templeton A., Seruga B., Amir E., Tannock I.: Honorary and Ghost-Authorship in Reports of Randomized Clinical Trials in Oncology Eur J Cancer. Oct 2016: 66:1–8
  • Theurich S., Rothschild S., Hoffmann M., Fabri M., Sommer A., Garcia-Marquez M., Thelen M., Schill  R., Schmid T., Koeberle D., Zippelius A., Baues C., Mauch C., Tigges C., Kreuter A., Borggrefe J., C., Merki von Bergwelt-Baildon M., Schlaak M.: Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in
  • Khoja L, Atenafu EG, Ye Q, Templeton AJ, Chappell M, Hogg D, Butler MO, Joshua AM. The full blood count as a biomarker of outcome and toxicity in ipilimumab treated cutaneous metastatic melanoma. Cancer Cancer Med. 2016 Oct;5(10):2792-2799. doi: 10.1002/cam4.878. Epub 2016 Sep 29. IF 2.915 (JCI 2015, rank 107/213 oncology)
  • Patients.with Advanced Malignant Melanoma Cancer Immunol Res. 2 Sep 2016: 4(9): 744–754
  • Sonpavde G, Pond GR, Templeton AJ, Kwon ED, De Bono JS. Impact of single agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2016 Sep 27.(JCI 2015, rank 64/213 oncology)
  • Vera-Badillo FE, Marc Napoleone M, Krzyzanowska MK, Alibhai SMH, Chan A-W, Ocana A, Seruga B,Templeton AJ, Amir E, Tannock IF. Bias in Reporting of Randomized Clinical Trialsin Oncology.Eur J Cancer. 2016 Jul;61:29-35.
  • Hess V., Winterhalder R., von Moos R., Widmer L., Stocker P., Jermann M., Herrmann R., Koeberle D.: Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome. Clin Colorectal Cancer. 30 Jul 2016: pii: S1533–0028(16) 30115-3
  • Seruga B., Templeton A., Vera-Badillo F., Ocana A., Amir E., Tannock I.:
    Under-reporting of harm in clinical trials. Lancet Oncol. May 2016: 17(5): e209–219
  • Templeton A., Diez Gonzalez L., Vera-Badillo F., Tibau A., Goldstein R.,Šeruga B., Srikanthan A., Pandiella A., Amir E., Ocana A.: Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations: A systematic review and metaregression. PLoS One. 5 May 2016: 11(5)
  • Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, Sánchez-Corrales V, Templeton AJ, Seruga B, Pandiella A,Amir E. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer:role of mitotic kinases. Oncotarget. 2016 Mar 16. IF 6.359 (JCI 2014, rank 20/210 oncology)
  • Ocaña A., Pérez-Peña J., Alcaraz-Sanabria A., Sánchez-Corrales V., Templeton A., Seruga B.,Pandiella A., Amir E.: In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. Oncotarget. 16 Mar 2016
  • Tibau A, Ocana A, Anguera G, Seruga B, Templeton AJ, Barnadas A, Amir E. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the U.S. Food and Drug Administration.JAMA Oncol. 2016 Mar 3.
  • Srikanthan A, Vera-Badillo F, Ethier J-L, Goldstein R, Templeton AJ, Ocana A, Seruga B, Amir E. Evolution in the Eligibility Criteria of Randomized Controlled Trials for Systemic Cancer Therapies. Cancer Treatment Reviews 2016; 43: 67-73  IF 7.588 (JCI 2014, rank 15/210 oncology)
  • Ocaña A, Pérez-Peña J, Díez-González L, Sánchez-Corrales V, Templeton A, Seruga B, Amir E, Pandiella A.Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1,and clinical outcome in breast cancer. Breast Cancer Res Treat. 2016 Feb;156(1):1-8. doi: 10.1007/s10549-016-3720-4. Epub 2016 Feb 20. IF 3.940 (JCI 2014, rank 62/210 oncology)
  • Templeton A., Knox J. , Lin X., Simantov R., Xie W., Lawrence N., Broom R., Fay A., Rini B., Donskov F., Bjarnason G. A., Smoragiewicz M., Kollmannsberger C., Kanesvaran R., Alimohamed N.,Hermanns T., Wells J., Amir E., Choueiri T., Heng D.: Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol. 25 Feb 2016 
  • Ocana A., Díez-González L., Templeton A., Vera-Badillo F., José Escribano M., Serrano G., Sánchez-Corrales V., Seruga B., Pandiella A., Amir E.: Circulating DNA and survival in solid tumors. Cancer Epidemiol Biomarkers Prev. Feb 2016: 25(2): 399–406
  • Niraula S., Templeton A., Vera-Badillo F., Joshua A., Sridhar S., Knox J., Cheung P., Yip P., Dodd A., Nugent Z., Tannock I.: Testosterone-Guided Schedule of Androgen Deprivation Therapy as an Alternative to a Fixed Schedule in Management of Prostate Cancer. Prostate. Feb 2016: 76(2): 2–242
  • Bhindi B., Hermanns T., Wei Y., Yu J., Richard P., Wettstein M., Templeton A. J., Li K., Sridhar S.,Jewett M., Fleshner N., Zlotta A., Kulkarni G.: Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer. 19 Jan 2016 : 114(2): 207–212
  • Seruga B, Templeton AJ, Vera Badillo FE, Ocana A, Amir E, Tannock IF. Under-reporting of harm in clinical trials. Lancet Oncology 2016: [accepted for publication on 22-Feb-2016] (Review)
  • 2015 van Soest RJ*, Templeton AJ*,  Vera-Badillo FE, Mercier F,  Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil to lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015 Apr;26(4):743-9.
  • 2015 Templeton AJ*, Ace O*, Amir E, Vera-Badillo F, Ocana A, Pond GR, Tannock IF. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur J Cancer. 2015 Apr;51(6):721-4.
  • 2015 Leibowitz-Amit R*, Templeton AJ*, Alibhai SM, Knox JJ, Sridhar SS, Tannock IF, Joshua AM. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2015 Jan;6(1):23-8.
  • Vera-Badillo FE, Marc Napoleone M, Krzyzanowska MK, Alibhai SMH, Chan A-W, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF. Bias in Reporting of Randomized Clinical Trials in Oncology. European Journal of Cancer 2016; [accepted for publication 10-Mar-2016]
  • Al Hashem H, Al-Mubarak M, Vera-Badillo FE, Templeton AJ, Ocana A, Seruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clin Oncol (R Coll Radiol). 2015 Nov 2. pii: S0936-6555(15)00386-6.
  • Ocana A, Ethier J-L, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget. 2015 Nov 24;6(37):39538-49.
  • Turner N, Wong H-L, Templeton AJ, Tripathy S, Rogers TW, Croxford M, Jones I, Sinnathamby M, Desai J, Tie J, Bae S, Christie M, Gibbs P, Tran B. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int J Cancer; 2015 Aug 13.
  • Vera-Badillo FE, Chang MC, Kuruzar G, Ocana A, Templeton AJ, Seruga B, Goldstein R, Bedard PL, Tannock IF, Amir E. Association between Androgen Receptor Expression, Ki-67 and the 21-Gene Recurrence Score in Non-metastatic, Lymph node-negative, Estrogen Receptor-positive and HER2-negative Breast Cancer. J Clin Pathol. 2015 Jun 15.
  • Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono J. Baseline Neutrophil-Lymphocyte Ratio (NLR) is Associated with Survival and Response to Treatment with Second-Line Chemotherapy for Advanced Prostate Cancer Independent of Baseline Steroid Use. Ann Oncol. 2015 Apr;26(4):750-5.
  • Tibau A, Bedard PL, Srikanthan A, Ethier J, Vera Badillo FE, Templeton AJ, Ocaña A, Seruga B, Barnadas A, Amir E. Author Financial Conflicts of Interest, Industry Funding and Clinical Practice Guidelines for Anti-Cancer Drugs. J Clin Oncol. 2015 Jan 1;33(1):100-6.
  • Sonpavde G*, Pond GR*, Templeton AJ, Fandi A, Tombal B, Rosenthal M, Armstrong AJ, Petrylak DP. The association of RECIST changes with survival in patients with metastatic castration resistant prostate cancer receiving docetaxel. Eur Urol. 2015 Oct 20.
  • Templeton AJ, Seruga B. Primum Non Nocere. Ann Oncol. 2015 Oct;26(10):2197-8. doi: 10.1093/annonc/mdv291. Epub 2015 Jul 13. (Letter).
  • Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo MD FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil to lymphocyte ratio. Cancer. 2014 Nov 1;120(21):3346-52.
  • Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124.
  • Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Šeruga B, Ocaña A, Tannock IF, Amir E. Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12.
  • Templeton AJ*, Diez Gonzalez L*, Ace O, Vera-Badillo F, Šeruga B, Jordán J, Amir E, Pandiella A, Ocaña A. Prognostic Relevance of Receptor Tyrosine Kinase Expression in Breast Cancer: A meta-analysis. Cancer Treat Rev. 2014 Oct;40(9):1048-55.
  • Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz S-F, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos R, Zaman K, Thürlimann BJK, Ruhstaller T. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast. 2014 Jun;23(3):244-9.
  • Leibowitz-Amit R*, Templeton AJ*, Omlin A, Pezaro C, Atenafu EG, Keizman D, Vera-Badillo F, Attard G, Knox J, Sridhar S, Tannock IF, de Bono JS, Joshua AM. Biomarkers associated with PSA response to abiraterone in men with metastatic castration-resistant prostate cancer. Ann Oncol. 2014 Mar;25(3):657-62.
  • Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton AJ, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. Eur Urol. 2014 Dec 15.
  • Rocha P*, Morgan CJ*, Templeton AJ, Pond GR, Naik G, Sonpavde G. Prognostic Impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. Oncol Res Treat. 2014;37(12):772-6.
  • Shao T, Wang L, Templeton AJ, Jang R, Margolis M, Sinaei M, Shoushtari H, Kim TK, McNamara M, Vera-Badillo F, Havill D, Tannock I. Use and Misuse of Waterfall Plots. J Natl Cancer Inst. 2014 Oct 29;106(12).
  • Leibowitz-Amit R, Seah J-A, Atenafu EG, Templeton AJ, Vera-Badillo FE, Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer: A Retrospective Review of the Princess Margaret Experience of (I) low dose abiraterone and (II) Prior Ketoconazole. Eur J Cancer. 2014 Sep;50(14):2399-407.
  • Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah J-A, Templeton AJ, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Retretment of Men With Metastatic Castrate-Resistant Prostate Cancer With Abiraterone. Prostate. 2014 Oct;74(14):1462-4.
  • Vera-Badillo FE, Napoleone M, Ocana A, Templeton AJ, Al-Mubarak M, Tannock IF, Amir E. Effect of Multifocality and Multicentricity on Outcome in Early Stage Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Research and Treatment 2014
  • Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic Therapy for Non-Clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-Analysis. Eur Urol. 2014 May 29.
  • Hermanns T, Bhindi B, Weia Y, Yua J, Bhatt J, Almatar A, Noon AP, Richard P, Jewett MAS, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer. 2014 Jul 29;111(3):444-51.
  • Ocana A, Vera-Badillo FE, Al-Mubarak M, Templeton AJ, Seruga B, Sánchez-Corrales V, Pandiella A, Amir A. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS ONE 9(4): e95219.
  • Sonpavde G*, Pond GR*, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang S-L, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. Prognostic impact of the neutrophil to lymphocyte ratio in men with metastatic castration resistant prostate cancer. Clin Genitourin Cancer. 2014 Oct;12(5):317-24.
  • McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Knox JJ. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014 Jun;50(9):1581-9.
  • McNamara MG, Lwin Z, Jiang H, Templeton AJ, Zadeh G, Berstein M, Chung C, Millar B-A, Laperriere N, Mason WP. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J Neurooncol. 2014 Mar;117(1):147-52.
  • Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E. Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-analysis. PLoS One. 2014 Feb 20;9(2):e88238.
  • Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff J, Wild P, Cathomas R*, Gillessen S*. Metformin in chemotherapy-naïve Castration Resistant Prostate Cancer (CRPC): A multicenter phase II study (SAKK 08/09). Eur Urol. 2014 Sep;66(3):468-74.
  • Vera-Badillo F, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard P, Al-Mubarak M, Seruga B, Tannock I,  Ocana A, Amir A. Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2014 Jan;106(1):djt319.
  • Schlaeppi MR, Templeton AJ. Komplementärmedizin in der Onkologie – Was der Grundversorger wissen sollte. Schweiz Med Forum 2014; 14(37): 689-93 (Review) (German version, original)
  • Schlaeppi MR, Templeton AJ.  La médecine complémentaire en oncologie Ce que doit savoir le médecin
  • Vera-Badillo FE, Ocana A, Templeton AJ, Tibau A, Amir E, Tannock IF. Raising Concern About the American Society of Clinical Oncology Conflict of Interest Policy Amendment. J Clin Oncol. 2014 Oct 1;32(28):3197.
  • Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF. Translating Clinical Trials to Clinical Practice: Outcomes of Men with Metastatic Castration Resistant Prostate Cancer Treated with Docetaxel and Prednisone in and out of Clinical Trials. Ann Oncol. 2013 Dec;24(12):2972-7.
  • Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Droege C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P-Y, Klingbiel D, Gillessen S. Phase 2 Trial of Single Agent Everolimus in Chemotherapy-naïve Patients with Castration Resistant Prostate Cancer (SAKK 08/08). Eur Urol. 2013 Jul;64(1):150-8.
  • Templeton AJ, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-Sectional Study of Self-Reported Physical Activity, Eating Habits and Use of Complementary Medicine in Breast Cancer Survivors. BMC Cancer. 2013 Mar 25;13:153.
  • Ocaña A, Vera-Badillo F, Šeruga B, Templeton AJ, Pandiella A, Amir E. HER3 over-expression and survival in solid tumors: A Meta-analysis. J Natl Cancer Inst. 2013 Feb 20;105(4):266-73.
  • Vera-Badillo FE, Al-Mubarak M, Templeton AJ, Amir E. Benefit and Harms of New Anti-Cancer Drugs. Curr Oncol Rep. 2013 Jun;15(3):270-5.
  • Omlin A, Gillessen S, Templeton A. Neues zur Behandlung des metastasierten Prostatkarzinoms. Swiss Medical Forum 2013; 3(23): 448–452 (Review) (German version, original)
  • Omlin A, Gillessen S, Templeton A. Du nouveau sur le traitement du carcinome prostatique métastatique. Forum Med Suisse 2013; 3(23): 448–452 (Review) (French Version)
  • Omlin A, Templeton AJ. ASCO 2013 Das Prostatakarzinom im Fokus klinischer Studien. Leading Opinions Hämatologie & Onkologie 2013; 4: 54 – 56 (Conference report)
  • Templeton AJ, Ocaña A, Šeruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Management of small HER2 overexpressing tumours. Breast Cancer Res Treat. 2012 Nov;136(1):289-93.
  • Hochstrasser A, Benz G, Joerger M, Templeton A, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event? Chemotherapy. 2012;58(1):84-8. de premier recours. Forum Med Suisse 2014; 14(37): 689-693 (Review) (French version)
  • Kälin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T, Aebersold R, Krek W, Gillessen S. Novel prognostic markers in the serum of patients with castration resistant prostate cancer derived from quantitative analysis of the Pten conditional knockout mouse proteome. Eur Urol. 2011 Dec;60(6):1235-43.
  • Cima I, Schiess R, Wild P, Kälin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen S, Aebersold R, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3342-7.
  • Joerger M, Templeton A, Koeberle D, Engler H, Riesen W F, Thurlimann B J K. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol. 2011 May;67(5):1137-44.
  • Thürlimann B, Templeton A. Challenges for clinical cancer research in Switzerland. Swiss Cancer League and the Foundation Cancer Research Switzerland, Research Report Edition 2011; 115 - 119 (Perspective)
  • Templeton A, Schlaeppi M. Anthroposophische Konzepte naturwissenschaftlich beleuchtet. Schweizerische Ärztezeitung 2011; 92: 1558 – 1559 (book review)
  • Templeton A. Die aktuellen Highlights vom ASCO zum Prostatakarzinom. Leading Opinions Onkologie 2011; 4: 40 - 42 (Conference report)
  • Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70.
  • Ruhstaller T, Templeton A, Ribi K, Schuller J, Borner M, Thierstein S, von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R. Intense Therapy in Patients with Locally Advanced Esophageal Cancer beyond Hope for Surgical Cure: A Prospective, Multicenter Phase II Trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie. 2010;33(5):222-8.
  • Huober J, Spirig C, Schoch O, Templeton A, Thürlimann B. Interstitial Pneumonitis after Treatment with Bevacizumab and Pegylated Liposomal Doxorubicin in a Patient with Metastatic Breast Cancer.  Chemotherapy. 2010;56(1):69-70.
  • Omlin A, Kälin M, Templeton A, Jungi M, Gillessen S, Graf H-J, Rothermundt C. Metastasiertes Prostatakarzinom – Behandlungsmöglichkeiten nach der Hormontherapie Swiss Medical Forum 2010; 10: 483 – 485 (Review)
  • Templeton A. ASCO Highlights 2011. SAKK Newsletter 2010; 19: 1 (Editorial)
  • Templeton A, Rothermundt C. Metastasiertes Nierenzellkarzinom - Moderne Behandlung bei fortgeschrittenem Stadium. Ars Medici 2010; 15: 598 - 602 (Review)
  • Templeton A*, Marra G*, Valtorta E, Heinimann K, Mueller H, Koeberle D, Gillessen S. Concordant colon tumors in monozygotic twins previously treated for prostate cancer. Fam Cancer. 2009;8(2):167-71.
  • Fehr M, Templeton A, Cogliatti S, Aebersold F, Gillessen S, Cathomas R. Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie. 2009 Oct;32(10):586-8.
  • Fokt RM*, Templeton A*, Gillessen S, Öhlschlegel C, Schmid HP. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol Int. 2009;83(1):122-4.
  • Templeton A, Thürlimann B, Jörger M. Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer Krebsbulletin 2009; 2: 114 - 117 (Review)
  • Templeton A, Schlegel M, Fleisch F, Rettenmund G, Schöbi B, Henz S, Eich G. Multilumen central venous catheters increase risk for catheter related blood stream infection - prospective surveillance study. Infection. 2008 Aug;36(4):322-7.
  • Templeton A, Brändle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008 Apr;19(4):824-5.
  • Templeton A, Hofer S, Töpfer M, Sommacal A, Fretz C, Cerny T, Gillessen S. Extraneural spread of a glioblastoma. Onkologie 2008; 31: 192 - 194 (Report of two cases)
  • Templeton A, Omlin A, Strasser F. An update on the pharmacological management of the cancer anorexia-cachexia-syndrome. European Journal of Palliative Care 2007: 14: 186 - 190 (Review)
  • Templeton A, Engeler S, Boggian K. Varizellenpneumonie. Swiss Medical Forum 2006; 6: 655 (Clinical diagnosis)
  • Rafeiner P*, Templeton A*, Vonesch HJ. Swollen leg with blisters. Praxis 2005; 94: 1569 - 1574 (Case report)
  • Templeton A, Vonesch H-J. Intoxikation mit GBL («liquid ecstasy»). Swiss Medical Forum 2005; 5: 115 - 116 (Case report)

Kontakt Claraspital

claraspital.ch
Unsere Telefonzeiten sind Montag bis Freitag von 08.00 - 17.00 Uhr. Ausserhalb der Telefonzeiten ist die Rezeption rund um die Uhr besetzt.

Rezeption:
T: 061 685 85 85